Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

Paying users zone. Data is hidden behind: .

  • Get 1-month access to Vertex Pharmaceuticals Inc. for $17.99, or

  • get full access to the entire website for at least 3 months from $49.99.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey

This is a one-time payment. There is no automatic renewal.

Cash Flow Statement

Beginner level

The cash flow statement provides information about a company’s cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company’s balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Vertex Pharmaceuticals Inc., consolidated cash flow statement

US$ in thousands

Microsoft Excel LibreOffice Calc
12 months ended: Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Net income (loss)
Stock-based compensation expense
Depreciation expense
Deferred income taxes, including benefit from valuation allowance release
Gains on equity securities
Increase in fair value of contingent consideration
Intangible asset impairment charges
Acquired in-process research and development
Deconsolidation of VIE
Other non-cash items, net
Accounts receivable, net
Inventories
Prepaid expenses and other assets
Accounts payable
Accrued expenses
Other liabilities
Changes in operating assets and liabilities
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities
Net cash provided by (used in) operating activities
Payments to acquire businesses, net of cash acquired
Purchases of available-for-sale debt securities
Maturities of available-for-sale debt securities
Sale of equity securities
Expenditures for property and equipment
Investment in equity securities
Investment in note receivable
Decrease in restricted cash due to deconsolidation of VIE
Purchase of in-process research and development
Increase (decrease) in restricted cash and cash equivalents (VIE)
Increase (decrease) in restricted cash and cash equivalents and other assets
Payment for acquisition of variable interest entity
Other investing activities
Net cash (used in) provided by investing activities
Issuances of common stock under benefit plans
Repurchases of common stock
Payments on finance leases
Advance from collaborator
Proceeds related to capital lease and construction financing lease obligations
Repayments of advanced funding
Payments on revolving credit facility
Payments on senior secured term loan
Proceeds from revolving credit facility
Payments of debt issuance costs
Other financing activities
Net cash provided by (used in) financing activities
Effect of changes in exchange rates on cash
Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period

Based on: 10-K (filing date: 2020-02-13), 10-K (filing date: 2019-02-13), 10-K (filing date: 2018-02-15), 10-K (filing date: 2017-02-23), 10-K (filing date: 2016-02-16).

Cash flow statement item Description The company
Net cash provided by (used in) operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Vertex Pharmaceuticals Inc.’s net cash provided by (used in) operating activities increased from 2017 to 2018 and from 2018 to 2019.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Vertex Pharmaceuticals Inc.’s net cash (used in) provided by investing activities increased from 2017 to 2018 but then decreased significantly from 2018 to 2019.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Vertex Pharmaceuticals Inc.’s net cash provided by (used in) financing activities decreased from 2017 to 2018 but then increased from 2018 to 2019 exceeding 2017 level.